Ian Estepan

Sr. Director, Corporate Affairs

Back to Speakers

Ian brings 16 years of experience in healthcare investing to fund the development of promising drug candidates in diverse therapeutic indications. Over the past 5 years he has combined this expertise with efforts to speed clinical development and patient access for patients with Duchenne muscular dystrophy. Ian currently heads up Corporate Affairs at Sarepta Therapeutics, with a focus on incorporating the patient perspectives into corporate strategic initiatives with the goal of expediting the advancement of clinical compounds through the regulatory process, such as identifying endpoints related to patient reported outcomes when traditional placebo controlled trials may not be feasible due to the lack of available patient populations in rare diseases.